Brand-name GLP-1s cost $1,000–1,300 per month without insurance. Compounded versions, prescribed through licensed US pharmacies, contain the same active ingredient at a fraction of the cost. Here's the honest comparison — what's identical, what's different, and what it means for patients.
The active pharmaceutical ingredient is the same: semaglutide is semaglutide whether it's in a Wegovy auto-injector pen or a compounded multi-dose vial. Tirzepatide is tirzepatide. The differences are packaging, dose flexibility, cost, and supply.
| Factor | Compounded | Brand |
|---|---|---|
| Active ingredient | Same (semaglutide or tirzepatide) | Same |
| Delivery | Multi-dose vial + syringes | Pre-filled auto-injector pen |
| Dose flexibility | Any dose (physician custom) | Fixed dose tiers only |
| Cost (cash pay) | $149–299/month (at YourMD) | $1,000–1,300/month |
| Insurance coverage | Typically cash-pay (HSA/FSA eligible) | Sometimes covered, PA often required |
| Pharmacy | PCAB-accredited 503A compounding pharmacy | Retail pharmacy |
| FDA regulation | State board + USP <797> sterile compounding standards | FDA-approved manufacturer |
| Availability | Generally stable | Periodic shortages (FDA shortage list) |
| Customization | Dose + optional additives (B12, MIC, L-carnitine) | Not possible |
Compounding was originally designed for situations where a commercial drug doesn't fit a patient's needs — pediatric dose, allergy to a commercial filler, unusual concentration requirement, or a drug shortage. Under federal law (FDCA Section 503A), physicians can prescribe compounded versions of approved drugs when the patient has a specific clinical need OR when the commercial product is on the FDA's official drug shortage list.
GLP-1 medications have been on the FDA drug shortage list intermittently since 2022. During shortage periods, compounding is explicitly legal. During non-shortage periods, compounding requires an individualized clinical justification documented by the prescribing physician. Your YourMD physician handles this documentation.
Brand Wegovy comes in fixed 0.25, 0.5, 1.0, 1.7, and 2.4 mg weekly doses. Zepbound comes in 2.5, 5, 7.5, 10, 12.5, and 15 mg. That's it. You either tolerate the next step up, or you don't.
In real clinical practice, many patients benefit from intermediate doses. Someone struggling with nausea on 1.0 mg semaglutide might do well at 0.75 mg — but that dose doesn't exist in the brand product. A patient plateauing on 7.5 mg tirzepatide might need 8.5 mg before jumping to 10 mg. Compounded multi-dose vials give your physician the ability to write any dose your clinical situation requires. For GLP-1 titration specifically, this is the single biggest practical advantage of compounding.
Not all compounding pharmacies are equal. Red flags to avoid:
YourMD only partners with licensed US 503A compounding pharmacies that are PCAB-accredited, operate under USP <797> sterile compounding standards, provide COAs from independent third-party labs, and ship cold-chain.
Brand GLP-1s are manufactured in pharmaceutical-grade facilities with FDA oversight. That's the gold standard. Compounded GLP-1s from PCAB-accredited 503A pharmacies are subject to state board regulation plus USP standards plus per-batch third-party testing. Not identical to FDA manufacturing oversight, but meaningful quality assurance. The risk you want to avoid isn't compounding per se — it's compounding from unlicensed, untested, non-US sources.
For most patients, compounded GLP-1 from a reputable US pharmacy is clinically equivalent, meaningfully cheaper, and more dose-flexible than the brand product. If insurance covers your brand-name prescription and you're tolerating fixed-dose titration well, brand is a perfectly reasonable choice. If you're cash-pay or want custom-dose flexibility, compounding is the better value for most patients.
Medical disclaimer: Educational content, not medical advice. Wegovy®, Ozempic®, Rybelsus® are trademarks of Novo Nordisk. Mounjaro®, Zepbound® are trademarks of Eli Lilly. Page reviewed by Teja V. Surapaneni, MD, MS (NV, WA, OR, WY). Last reviewed: April 17, 2026